COMy 2021 | Optimizing immunotherapy to improve outcomes in myeloma
Paola Neri, MD, PhD, University of Calgary, Calgary, AB, Canada, discusses the current strategies to reverse immune deregulation in patients with multiple myeloma. Immune dysregulation is a critical feature of myeloma, as it is not only important in disease pathogenesis but also dictates immunotherapy responses. Tremendous growth in the immunotherapy field in myeloma has meant numerous classes of agent are available, including immune checkpoint inhibitors, monoclonal antibodies, CAR T-cell therapy and bispecific T-cell engagers. Dr Neri talks on the need for further optimization of these therapies to improve outcomes, as well as work underway to target the bone marrow microenvironment and establish new targets for immunotherapies. This interview took place during the 7th World Congress on Controversies in Multiple Myeloma (COMy), 2021.
Disclosures
Speaker bureau/honoraria: BMS, Janssen
Consulting fees: BMS, Janssen
